Laurus Labs Galenvs Acquisition: A Small Ticket Aimed at Oligonucleotide Capability
The Laurus Labs Galenvs acquisition is a US$3.75 million option on oligonucleotide skills. Deal math, strategy and risks.
Tag: TIDES therapeutics
Read More